Drug Profile

OT 202

Alternative Names: OT-202

Latest Information Update: 05 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ocumension Therapeutics
Class Eye disorder therapies; Pyrazoles
Mechanism of Action Protein tyrosine kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Dry eyes

Most Recent Events

31 Jul 2026 Ocumension Therapeutics plans a phase III trial for Dry eyes (Treatment-experienced) in China (Ophthalmic, Drops) (NCT07740564)
21 Mar 2024 Phase-II clinical trials in Dry eyes in China (Ophthalmic), prior to March 2024
21 Mar 2024 Ocumension Therapeutics completes enrolment in the phase II trial in Dry eyes in China (Ophthalmic)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com